Krystal Biotech (KRYS)

Nasdaq Health Care Biotechnology S&P MidCap 400

$300.88

+0.63 (+0.21%)

Close of Nov 06, 2026 · end-of-day data

Source: Krystal Biotech's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 03, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD

Fiscal year	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$0	$0	$50.70M	$290.51M	$389.13M
Research & development	$27.88M	$42.46M	$46.43M	$53.58M	$58.05M
Selling, general & admin	—	$77.73M	$98.29M	$113.63M	$146.74M
Operating income	-$68.28M	-$145.20M	-$109.62M	$65.75M	$161.29M
Interest expense	$1.49M	$0	$0	—	—
Pre-tax income	-$69.57M	-$139.97M	$12.90M	$95.36M	$189.47M
Income tax	$0	$0	$1.97M	$6.20M	-$15.36M
Net income	-$69.57M	-$139.97M	$10.93M	$89.16M	$204.83M
EBITDA	-$65.51M	-$141.14M	-$104.61M	$71.72M	$167.02M
EPS (basic)	$-3.13	$-5.49	$0.40	$3.12	$7.08
EPS (diluted)	$-3.13	$-5.49	$0.39	$3.00	$6.84
Diluted shares	22.20M	25.49M	27.75M	29.74M	29.95M
Operating margin	—	—	-216.2%	22.6%	41.5%
Net margin	—	—	21.6%	30.7%	52.6%

Balance sheet

fiscal years · USD

Fiscal year	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$341.25M	$161.90M	$358.33M	$344.87M	$496.30M
Short-term investments	$96.85M	$217.27M	$173.85M	$252.65M	$331.49M
Receivables	—	$0	$42.04M	$104.75M	$127.42M
Inventory	—	$0	$6.99M	$26.51M	$40.48M
Total current assets	$442.27M	$383.78M	$587.91M	$742.04M	$1.02B
Total assets	$626.29M	$558.45M	$818.36M	$1.06B	$1.33B
Total current liabilities	$25.74M	$28.85M	$33.09M	$102.00M	$102.94M
Total liabilities	$32.72M	$36.22M	$39.71M	$109.46M	$114.23M
Shareholders' equity	$593.58M	$522.23M	$778.64M	$946.38M	$1.22B

Cash flow

fiscal years · USD

Fiscal year	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$47.94M	-$100.57M	-$88.80M	$123.42M	$200.87M
Capital expenditures	$68.34M	$52.98M	$11.80M	$4.24M	$11.95M
Free cash flow	-$116.27M	-$153.55M	-$100.60M	$119.18M	$188.91M
Investing cash flow	-$226.77M	-$114.08M	$82.64M	-$163.44M	-$58.42M
Financing cash flow	$347.69M	$35.35M	$202.75M	$27.01M	$8.71M
Stock-based compensation	$15.32M	$33.23M	$39.93M	$49.13M	$54.51M
Depreciation & amortization	$2.77M	$4.05M	$5.01M	$5.97M	$5.72M

Income statement

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	$42.14M	$45.25M	$70.28M	$83.84M	$91.14M	$88.18M	$96.04M	$97.80M	$107.11M	$116.36M	$119.22M	$127.34M
Research & development	$11.37M	$10.96M	$15.58M	$13.51M	$13.53M	$14.26M	$14.41M	$14.59M	$14.79M	$15.33M	$14.52M	$14.89M
Selling, general & admin	$24.65M	$26.06M	$27.63M	$28.67M	$31.29M	$32.65M	$35.07M	$37.58M	$41.45M	$41.01M	$39.85M	$33.75M
Operating income	$3.25M	-$6.68M	$8.57M	$22.47M	$41.38M	$36.25M	$39.40M	$41.37M	$44.27M	$53.69M	$58.42M	$71.14M
Pre-tax income	$10.66M	$932.00K	$16.05M	$29.77M	$48.61M	$43.60M	$46.77M	$47.97M	$51.13M	$61.44M	$66.08M	$80.14M
Income tax	$1.97M	$0	$477.00K	$2.59M	$3.13M	$7.86M	$8.44M	-$31.40M	-$269.00K	$5.51M	$11.31M	$17.08M
Net income	$8.69M	$932.00K	$15.57M	$27.18M	$45.48M	$35.73M	$38.33M	$79.36M	$51.40M	$55.93M	$54.77M	$63.07M
EBITDA	$4.77M	-$5.26M	$10.37M	$23.77M	$42.74M	$37.66M	$40.70M	$42.77M	$45.83M	$55.21M	$59.82M	$72.64M
EPS (basic)	$0.32	$0.03	$0.54	$0.95	$1.59	$1.24	$1.33	$2.74	$1.77	$1.91	$1.85	$2.13
EPS (diluted)	$0.31	$0.03	$0.53	$0.91	$1.53	$1.20	$1.29	$2.66	$1.70	$1.83	$1.79	$2.05
Diluted shares	367.00K	29.29M	29.64M	29.90M	71.00K	29.87M	29.75M	29.83M	122.00K	30.51M	30.66M	30.84M
Operating margin	7.7%	-14.8%	12.2%	26.8%	45.4%	41.1%	41.0%	42.3%	41.3%	46.1%	49.0%	55.9%
Net margin	20.6%	2.1%	22.2%	32.4%	49.9%	40.5%	39.9%	81.2%	48.0%	48.1%	45.9%	49.5%

Balance sheet

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Cash & equivalents	$358.33M	$359.01M	$345.79M	$373.97M	$344.87M	$308.77M	$353.83M	$392.60M	$496.30M	$501.31M	$427.74M	$462.84M
Short-term investments	$173.85M	$179.25M	$213.83M	$214.36M	$252.65M	$308.08M	$328.16M	$338.46M	$331.49M	$322.09M	$417.89M	$449.01M
Receivables	$42.04M	$104.75M	$103.24M	$97.30M	$104.75M	$103.26M	$111.44M	$129.63M	$127.42M	$127.02M	$138.66M	$133.12M
Inventory	$6.99M	$11.04M	$12.18M	$18.58M	$26.51M	$29.94M	$31.04M	$37.63M	$40.48M	$42.65M	$45.56M	$50.79M
Total current assets	$587.91M	$602.25M	$682.77M	$713.16M	$742.04M	$766.80M	$841.35M	$925.65M	$1.02B	$1.02B	$1.06B	$1.12B
Total assets	$818.36M	$853.30M	$917.66M	$982.32M	$1.06B	$1.07B	$1.14B	$1.24B	$1.33B	$1.40B	$1.50B	$1.59B
Total current liabilities	$33.09M	$47.59M	$71.85M	$89.53M	$102.00M	$79.49M	$86.90M	$91.27M	$102.94M	$107.80M	$127.40M	$142.14M
Total liabilities	$39.71M	$54.05M	$78.77M	$96.47M	$109.46M	$89.74M	$97.75M	$102.22M	$114.23M	$120.24M	$141.52M	$150.47M
Shareholders' equity	$778.64M	$799.24M	$838.89M	$885.85M	$946.38M	$984.67M	$1.04B	$1.14B	$1.22B	$1.28B	$1.36B	$1.44B

Cash flow

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Operating cash flow	-$7.23M	$15.89M	-$4.17M	$58.86M	$52.84M	$30.97M	$52.73M	$39.66M	$77.51M	$80.38M	$74.79M	$91.25M
Capital expenditures	$1.85M	$1.26M	$1.13M	$1.05M	$801.00K	$6.20M	$1.90M	$1.70M	$2.14M	$7.15M	$3.56M	$996.00K
Free cash flow	-$9.08M	$14.63M	-$5.30M	$57.81M	$52.04M	$24.77M	$50.83M	$37.95M	$75.37M	$73.23M	$71.22M	$90.25M
Investing cash flow	-$10.16M	-$25.98M	-$19.35M	-$34.33M	-$83.78M	-$54.77M	-$10.53M	-$4.29M	$11.16M	-$63.58M	-$161.58M	-$57.98M
Financing cash flow	$2.62M	$10.58M	$10.64M	$3.37M	$2.43M	-$12.47M	$1.80M	$3.71M	$15.67M	-$10.46M	$15.05M	$3.41M
Stock-based compensation	$9.85M	$9.30M	$13.16M	$13.32M	$13.36M	$13.48M	$14.12M	$13.15M	$13.76M	$13.61M	$14.16M	$13.94M
Depreciation & amortization	$1.52M	$1.43M	$1.80M	$1.30M	$1.36M	$1.41M	$1.30M	$1.40M	$1.56M	$1.52M	$1.40M	$1.50M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.